JOP20220102A1 - مثبطات المُسْتقبلة الأدرينِية adrac2 - Google Patents
مثبطات المُسْتقبلة الأدرينِية adrac2Info
- Publication number
- JOP20220102A1 JOP20220102A1 JOP/2022/0102A JOP20220102A JOP20220102A1 JO P20220102 A1 JOP20220102 A1 JO P20220102A1 JO P20220102 A JOP20220102 A JO P20220102A JO P20220102 A1 JOP20220102 A1 JO P20220102A1
- Authority
- JO
- Jordan
- Prior art keywords
- prevention
- treatment
- disorders
- diseases
- peripheral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات كربوكساميد حلقي غير متجانس يحمل بدائل جديدة، وبعمليات لتحضيرها، وباستخدامها بمفردها أو في توليفات لمعالجة و/أو الوقاية من الأمراض وباستخدامها لإنتاج الأدوية المعدة لمعالجة و/أو الوقاية من الأمراض، بشكل خاص لمعالجة و/أو الوقاية من صعوبات التنفس بما في ذلك صعوبات التنفس الناجمة عن النوم مثل انقطاع النفس المركزي والانسدادي أثناء النوم، الشخير (الشخير الأولي والشخير الانسدادي)، عسر البلع، اضطرابات الأوعية الدموية الطرفية والقلبية بما في ذلك اعتلال الأوعية الدقيقة السكري واضطرابات الجهاز العصبي المحيطي والمركزي بما في ذلك الاضطرابات العصبية التنكسية والالتهابات العصبية
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19207536 | 2019-11-06 | ||
PCT/EP2020/081097 WO2021089683A1 (en) | 2019-11-06 | 2020-11-05 | Inhibitors of adrenoreceptor adrac2 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220102A1 true JOP20220102A1 (ar) | 2023-01-30 |
Family
ID=68531352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0102A JOP20220102A1 (ar) | 2019-11-06 | 2020-11-05 | مثبطات المُسْتقبلة الأدرينِية adrac2 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230115270A1 (ar) |
EP (1) | EP4021905A1 (ar) |
JP (1) | JP2023500263A (ar) |
KR (1) | KR20220098160A (ar) |
CN (1) | CN114929694A (ar) |
AR (1) | AR120404A1 (ar) |
AU (1) | AU2020377470A1 (ar) |
BR (1) | BR112022008146A2 (ar) |
CA (1) | CA3160035A1 (ar) |
CO (1) | CO2022005783A2 (ar) |
CR (1) | CR20220195A (ar) |
EC (1) | ECSP22035103A (ar) |
IL (1) | IL292656A (ar) |
JO (1) | JOP20220102A1 (ar) |
MX (1) | MX2022005414A (ar) |
PE (1) | PE20221025A1 (ar) |
TW (1) | TW202132292A (ar) |
WO (1) | WO2021089683A1 (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022026398A2 (pt) * | 2020-07-06 | 2023-01-17 | Bayer Ag | Combinação de antagonista de receptor ¿2 adrenérgico subtipo c (alfa-2c) com bloqueador de canal task1/3 para tratamento da apneia do sono |
TW202342033A (zh) | 2021-12-22 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之α2-腎上腺素受體亞型C(α-2C)拮抗劑與正腎上腺素再吸收抑制劑之組合 |
TW202342011A (zh) | 2021-12-22 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之α2-腎上腺素受體亞型C(α-2C)拮抗劑與蕈毒鹼受體拮抗劑之組合 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
EP2077841A1 (en) | 2006-10-30 | 2009-07-15 | Glaxo Group Limited | Novel substituted pyrimidines as cysteine protease inhibitors |
WO2008060568A2 (en) * | 2006-11-15 | 2008-05-22 | Neurogen Corporation | Amide-substituted aryl piperidines |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
EP2682394A1 (de) | 2010-07-09 | 2014-01-08 | Bayer Intellectual Property GmbH | 1H-Pyrazolo[3,4-b]pyridin-Triazine Verbindungen und ihre Verwendung zur Behandlung bzw. Prophylaxe von Herz-Kreislauf-Erkrankungen |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
CN106029648A (zh) * | 2013-12-19 | 2016-10-12 | 拜耳制药股份公司 | 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物 |
JP2017503778A (ja) | 2013-12-19 | 2017-02-02 | バイエル ファーマ アクチエンゲゼルシャフト | アドレナリン受容体α2C拮抗薬としての置換されたビピペリジニル誘導体 |
CA3007699A1 (en) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same |
US10759794B2 (en) | 2015-12-10 | 2020-09-01 | Bayer Pharma Aktiengesellschaft | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders |
JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
-
2020
- 2020-11-05 TW TW109138601A patent/TW202132292A/zh unknown
- 2020-11-05 AR ARP200103077A patent/AR120404A1/es unknown
- 2020-11-05 AU AU2020377470A patent/AU2020377470A1/en active Pending
- 2020-11-05 JP JP2022525189A patent/JP2023500263A/ja active Pending
- 2020-11-05 JO JOP/2022/0102A patent/JOP20220102A1/ar unknown
- 2020-11-05 CR CR20220195A patent/CR20220195A/es unknown
- 2020-11-05 WO PCT/EP2020/081097 patent/WO2021089683A1/en active Application Filing
- 2020-11-05 EP EP20800159.4A patent/EP4021905A1/en active Pending
- 2020-11-05 IL IL292656A patent/IL292656A/en unknown
- 2020-11-05 CN CN202080091881.6A patent/CN114929694A/zh active Pending
- 2020-11-05 BR BR112022008146A patent/BR112022008146A2/pt unknown
- 2020-11-05 CA CA3160035A patent/CA3160035A1/en active Pending
- 2020-11-05 PE PE2022000716A patent/PE20221025A1/es unknown
- 2020-11-05 MX MX2022005414A patent/MX2022005414A/es unknown
- 2020-11-05 KR KR1020227018406A patent/KR20220098160A/ko unknown
- 2020-11-05 US US17/774,459 patent/US20230115270A1/en active Pending
-
2022
- 2022-05-03 EC ECSENADI202235103A patent/ECSP22035103A/es unknown
- 2022-05-03 CO CONC2022/0005783A patent/CO2022005783A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023500263A (ja) | 2023-01-05 |
TW202132292A (zh) | 2021-09-01 |
IL292656A (en) | 2022-07-01 |
MX2022005414A (es) | 2022-05-26 |
CN114929694A (zh) | 2022-08-19 |
AR120404A1 (es) | 2022-02-09 |
CR20220195A (es) | 2022-06-24 |
EP4021905A1 (en) | 2022-07-06 |
BR112022008146A2 (pt) | 2022-07-19 |
PE20221025A1 (es) | 2022-06-16 |
ECSP22035103A (es) | 2022-06-30 |
US20230115270A1 (en) | 2023-04-13 |
CO2022005783A2 (es) | 2022-05-20 |
AU2020377470A1 (en) | 2022-05-26 |
CA3160035A1 (en) | 2021-05-14 |
KR20220098160A (ko) | 2022-07-11 |
WO2021089683A1 (en) | 2021-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005414A (es) | Inhibidores de adrenoreceptor adrac2. | |
PH12018500162A1 (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
PH12019502828A1 (en) | Diazabicylic substituted imidazopyrimides and their use for the treatment of breathing disorders | |
MY197738A (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
NZ736432A (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
MY197262A (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
MX337548B (es) | Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide. | |
WO2014078575A3 (en) | Novel orally bioavailable breathing control modulating compounds, and methods of using same | |
AU2017379247A8 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
EP4252755A3 (en) | Therapeutic compounds | |
MX2022014925A (es) | Moduladores de il-17a. | |
MX2021000737A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y composicion farmaceutica que los comprende. | |
MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
MX2020013689A (es) | Hidroxipropil-?-ciclodextrina novedosa y proceso para la producción de esta. | |
MX2021012579A (es) | Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos. | |
MX2021004860A (es) | Piridazinas novedosas. | |
MX2021002017A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
WO2020039088A3 (en) | Aromatic molecules for use in the treatment of pathological conditions | |
PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
WO2020039092A3 (en) | Aromatic molecules for use in the treatment of pathological conditions | |
ATE481379T1 (de) | N-alkylcarbonyl-d- aminohydroxyalkylesterverbindungen und ihre verwendung | |
Manassero | Mepivacaine/metoprolol | |
MX2022006630A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso. |